Alemtuzumab and Rituximab in Aplastic Anemia

Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia

The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.

Inclusion Criteria:

• Patients with aplastic anemia diagnosis

Exclusion Criteria:

• Patients with prior treatment with monoclonal antibodies and/or antithymocyte globulin.
• Patients with a diagnosis or history of HIV/AIDS, Hepatitis B, Hepatitis C, Cytomegalovirus.
• Patients who do not agree to sign a Letter of Informed Consent.